Tonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights May 12, 2020 • 7:30 AM EDT
Tonix Pharmaceuticals Enters into Research Collaboration and Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines, TNX-1810, TNX-1820 and TNX-1830, for the Prevention of COVID-19 May 7, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia April 24, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals to Deliver Virtual Presentation and Participate in Panel Discussion for Planet MicroCap Showcase Virtual Investor Conference 2020 April 20, 2020 • 7:30 AM EDT
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights March 24, 2020 • 5:15 PM EDT
Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit March 23, 2020 • 4:30 PM EDT
Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct Offering March 3, 2020 • 5:00 PM EST
Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market February 28, 2020 • 8:45 AM EST
Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800) February 26, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Announces Closing of $7.5 million Public Offering February 11, 2020 • 4:01 PM EST
